FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:164-170 January 21, 1993 Number 3 Next

	Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Accelerated coronary artery disease is a major cause of late morbidity and mortality among heart-transplant recipients. Because calcium-channel blockers can suppress diet-induced atherosclerosis in laboratory animals, we assessed the efficacy of diltiazem in preventing coronary artery disease in transplanted hearts.

Methods Consecutive eligible cardiac-transplant recipients were randomly assigned to receive diltiazem (n = 52) or no calcium-channel blocker (n = 54). Coronary angiograms obtained early after cardiac transplantation and annually thereafter were used for the visual assessment of the extent of coronary artery disease. The average diameters of identical coronary artery segments were measured on the angiograms obtained at base line and at the first and second follow-up examinations.

Results In the 57 patients who had all three angiograms, the average coronary artery diameter (±SD) decreased in the group that received no calcium-channel blocker from 2.41 ±0.27 mm at base line to 2.19 ±0.28 mm at one year, and to 2.22 ±0.26 mm at two years (P<0.001 for both years). The average diameter in the diltiazem group changed little from the base-line value of 2.32 ±0.22 mm (2.32 ±0.27 mm at one year and 2.36 ±0.22 mm at two years). The average change in the diameter of the segment differed significantly between the two treatment groups (P<0.001), and the estimated effect of treatment changed only negligibly after adjustment for other relevant clinical variables. New angiographic evidence of coronary artery disease developed in 14 patients not given calcium-channel blockers, as compared with 5 diltiazem-treated patients (P = 0.082). Coronary stenoses greater than 50 percent of the luminal diameter developed in seven patients not given calcium-channel blockers, as compared with two patients given diltiazem; death due to coronary artery disease or retransplantation occurred in five patients in the group that did not receive calcium-channel blockers and in none of those who received diltiazem.

Conclusions Our preliminary results suggest that diltiazem can prevent the usual reduction in the diameter of the coronary artery in cardiac-transplant recipients, but further follow-up will be required to determine whether diltiazem can decrease the long-term incidence of symptomatic coronary artery disease.

Source Information

From the Division of Cardiovascular Medicine (J.S.S., S.-Z.G., E.L.A., S.A.H.), the Department of Statistics (I.J., D.B.B.), and the Department of Cardiothoracic Surgery (V.W., E.B.S.), Stanford University School of Medicine, Stanford, Calif.

Address reprint requests to Dr. Schroeder at the Division of Cardiovascular Medicine, CVRC, Stanford University School of Medicine, Stanford, CA 94305.

Full Text of this Article

Related Letters:

Diltiazem in the Prevention of Coronary Artery Disease in Heart-Transplant Recipients
Pollak R., Fabrega A. J., Schroeder J.S., Gao S.-Z., Alderman E.L.
Extract | Full Text  
N Engl J Med 1993; 328:1851-1852, Jun 24, 1993. Correspondence

This article has been cited by other articles:

• Schmauss, D., Weis, M. (2008). Cardiac Allograft Vasculopathy: Recent Developments. Circulation 117: 2131-2141 [Abstract] [Full Text]  
• Mudge, G. H. Jr (2007). Sirolimus and Cardiac Transplantation: Is It the "Magic Bullet"?. Circulation 116: 2666-2668 [Full Text]  
• Martin-Ventura, J. L., Tunon, J., Duran, M. C., Blanco-Colio, L. M., Vivanco, F., Egido, J. (2006). Vascular Protection of Dual Therapy (Atorvastatin-Amlodipine) in Hypertensive Patients. J. Am. Soc. Nephrol. 17: S189-S193 [Abstract] [Full Text]  
• Isobe, M., Kosuge, H., Suzuki, J.-i. (2006). T Cell Costimulation in the Development of Cardiac Allograft Vasculopathy: Potential Targets for Therapeutic Interventions. Arterioscler. Thromb. Vasc. Bio. 26: 1447-1456 [Abstract] [Full Text]  
• Lindenfeld, J., Page, R. L. II, Zolty, R., Shakar, S. F., Levi, M., Lowes, B., Wolfel, E. E., Miller, G. G. (2005). Drug Therapy in the Heart Transplant Recipient: Part III: Common Medical Problems. Circulation 111: 113-117 [Full Text]  
• Suzuki, S., Nishimaki-Mogami, T., Tamehiro, N., Inoue, K., Arakawa, R., Abe-Dohmae, S., Tanaka, A. R., Ueda, K., Yokoyama, S. (2004). Verapamil Increases the Apolipoprotein-Mediated Release of Cellular Cholesterol by Induction of ABCA1 Expression Via Liver X Receptor-Independent Mechanism. Arterioscler. Thromb. Vasc. Bio. 24: 519-525 [Abstract] [Full Text]  
• Mancini, D., Pinney, S., Burkhoff, D., LaManca, J., Itescu, S., Burke, E., Edwards, N., Oz, M., Marks, A. R. (2003). Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy. Circulation 108: 48-53 [Abstract] [Full Text]  
• Vassalli, G., Gallino, A., Weis, M., von Scheidt, W., Kappenberger, L., von Segesser, L.K., Goy, J.-J., on behalf of the Working Group Microcirculation of, (2003). Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 24: 1180-1188 [Abstract] [Full Text]  
• Weis, M., Cooke, J. P. (2003). Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway. Arterioscler. Thromb. Vasc. Bio. 23: 567-575 [Abstract] [Full Text]  
• Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Krobot, K., Steinbeck, G., Seidel, D., Reichart, B. (2003). Simvastatin Initiated Early After Heart Transplantation: 8-Year Prospective Experience. Circulation 107: 93-97 [Abstract] [Full Text]  
• Sechtem, U. (2001). Do heart transplant recipients need annual coronary angiography?. Eur Heart J 22: 895-897  
• John, R., Rajasinghe, H. A., Itescu, S., Suratwalla, S., Lietz, K., Weinberg, A. D., Kocher, A., Mancini, D. M., Drusin, R. E., Oz, M. C., Smith, C. R., Rose, E. A., Edwards, N. M. (2001). Factors affecting long-term survival (>10 years) after cardiac transplantation in the cyclosporine era. J Am Coll Cardiol 37: 189-194 [Abstract] [Full Text]  
• Aranda, J. M. Jr., Hill, J. (2000). Cardiac Transplant Vasculopathy. Chest 118: 1792-1800 [Abstract] [Full Text]  
• Sharifi, M., Siraj, Y., O'Donnell, J., Pompili, V. J. (2000). Coronary Angioplasty and Stenting in Orthotopic Heart Transplants: A Fruitful Act or a Futile Attempt?. ANGIOLOGY 51: 809-815 [Abstract]  
• Autieri, M. V., Carbone, C., Mu, A. (2000). Expression of Allograft Inflammatory Factor-1 Is a Marker of Activated Human Vascular Smooth Muscle Cells and Arterial Injury. Arterioscler. Thromb. Vasc. Bio. 20: 1737-1744 [Abstract] [Full Text]  
• Schwarzacher, S. P., Uren, N. G., Ward, M. R., Schwarzkopf, A., Giannetti, N., Hunt, S., Fitzgerald, P. J., Oesterle, S. N., Yeung, A. C. (2000). Determinants of Coronary Remodeling in Transplant Coronary Disease : A Simultaneous Intravascular Ultrasound and Doppler Flow Study. Circulation 101: 1384-1389 [Abstract] [Full Text]  
• Cooke, J. P (2000). The endothelium: a new target for therapy. Vasc Med 5: 49-53 [Abstract]  
• Rossignol, D. A., Kipreos, B., Akosah, K., Mohanty, P. K. (1999). Accelerated Transplant Coronary Artery Disease and Massive Silent Acute Myocardial Infarction in a Heart Transplant Patient: A Case Report and Brief Review of Literature. ANGIOLOGY 50: 947-953 [Abstract]  
• Young, J. B. (1999). Allograft Vasculopathy : Diagnosing the Nemesis of Heart Transplantation. Circulation 100: 458-460 [Full Text]  
• Valantine, H. A., Gao, S.-Z., Menon, S. G., Renlund, D. G., Hunt, S. A., Oyer, P., Stinson, E. B., Brown, B. W. Jr, Merigan, T. C., Schroeder, J. S. (1999). Impact of Prophylactic Immediate Posttransplant Ganciclovir on Development of Transplant Atherosclerosis : A Post Hoc Analysis of a Randomized, Placebo-Controlled Study. Circulation 100: 61-66 [Abstract] [Full Text]  
• Pethig, K., Heublein, B., Meliss, R. R., Haverich, A. (1999). Volumetric remodeling of the proximal left coronary artery: Early versus late after heart transplantation. J Am Coll Cardiol 34: 197-203 [Abstract] [Full Text]  
• Robbins, R. C., Barlow, C. W., Oyer, P. E., Hunt, S. A., Miller, J. L., Reitz, B. A., Stinson, E. B., Shumway, N. E. (1999). THIRTY YEARS OF CARDIAC TRANSPLANTATION AT STANFORD UNIVERSITY. J. Thorac. Cardiovasc. Surg. 117: 939-951 [Abstract] [Full Text]  
• Jain, S. P., Ramee, S. R., White, C. J., Mehra, M. R., Ventura, H. O., Zhang, S., Jenkins, J. S., Collins, T. J. (1998). Coronary stenting in cardiac allograft vasculopathy. J Am Coll Cardiol 32: 1636-1640 [Abstract] [Full Text]  
• Hunt, S. A., Frazier, O.H. (1998). Mechanical Circulatory Support and Cardiac Transplantation. Circulation 97: 2079-2090 [Full Text]  
• Bouchard, D., Despatis, M.-A., Buluran, J., Cartier, R. (1997). Vascular Effects of Cyclosporin A and Acute Rejection in Canine Heart Transplantation. Ann. Thorac. Surg. 64: 1325-1330 [Abstract] [Full Text]  
• Weis, M., von Scheidt, W. (1997). Cardiac Allograft Vasculopathy : A Review. Circulation 96: 2069-2077 [Abstract] [Full Text]  
• Lim, T. T., Botas, J., Ross, H., Liang, D. H., Theodore, J., Hunt, S. A., Oesterle, S. N., Yeung, A. C. (1996). Are Heart-Lung Transplant Recipients Protected From Developing Transplant Coronary Artery Disease?: A Case-Matched Intracoronary Ultrasound Study. Circulation 94: 1573-1577 [Abstract] [Full Text]  
• Keogh, A., Spratt, P., McCosker, C., Macdonald, P., Mundy, J., Kaan, A. (1995). Ketoconazole to Reduce the Need for Cyclosporine after Cardiac Transplantation. NEJM 333: 628-634 [Abstract] [Full Text]  
• Sarris, G. E., Moore, K. A., Schroeder, J. S., Hunt, S. A., Fowler, M. B., Valantine, H. B., Vagelos, R. H., Billingham, M. E., Oyer, P. E., Stinson, E. B., Reitz, B. A., Shumway, N. E. (1994). Cardiac transplantation: The Stanford experience in the cyclosporine era. J. Thorac. Cardiovasc. Surg. 108: 240-252 [Abstract] [Full Text]  
• Gibbons, G. H., Dzau, V. J. (1994). The Emerging Concept of Vascular Remodeling. NEJM 330: 1431-1438 [Full Text]  
• Pollak, R., Fabrega, A. J., Schroeder, J.S., Gao, S.-Z., Alderman, E.L. (1993). Diltiazem in the Prevention of Coronary Artery Disease in Heart-Transplant Recipients. NEJM 328: 1851-1852 [Full Text]